Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)GlobeNewsWire • Thursday
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous DosingGlobeNewsWire • Wednesday
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • Tuesday
Libtayo® (cemiplimab) Approved in the European Union (EU) for Extended Dosing and Faster Infusion Times Across Skin, Lung and Cervical Cancer IndicationsGlobeNewsWire • Tuesday
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?The Motley Fool • 11/14/26
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic SymptomsGlobeNewsWire • 11/12/26
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH TranscriptSeeking Alpha • 11/10/26
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80%MarketBeat • 11/10/26
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLDGlobeNewsWire • 11/08/26
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades'Benzinga • 11/03/26
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 ResultsBenzinga • 11/02/26